Browse our collection of papers in
GlaxoSmithKline (GSK)
C/L/173. Intellectual Property Negotiation: GSK vs. Harbin
- WORDS:
- 3300
- DATE:
- 2007
- PRICE:
- 39.99 GBP
This report has been produced to analyse the negotiations regarding the intellectual property rights agreement between GlaxoSmithKline, one of the leading research based pharmaceutical company and Harbin Pharmaceutical Group Holding Co. Ltd., a state holding Sino Foreign Joint Venture for the drug Cervarix TM, which is vaccine against human papillomavirus (HPV) that causes cervical cancer. The negotiations ended with GSK signing a 15 year contract with Harbin and approved for distribution in Australia in May 2007 for women aged 10 to 45
KEYWORDS: GSK, Harbin, China, Negotiation, IP, Intellectual Property, Pharmaceutical Industry,
Other Papers On: GlaxoSmithKline (GSK)
Other Papers On: Intellectual Property Law
Subject Catalogue
- Dissertations and Proposals
- Analysis of Companies
- Analysis of Industries
- Architecture, Design and Technology
- Computing and Mathematics
- E-Commerce and E-Business
- Economics
- Education
- Engineering
- Fashion and Culture
- Finance and Accounting
- General Business
- History
- Hospitality and Tourism
- Human Resource Management
- International Relations
- Law
- Literature, Language and Theatre Studies
- Management and Organisational Behaviour
- Marketing
- Media, Music and Art
- Operations Management
- Philosophy
- Politics
- Psychology
- Science, Medicine and Nursing
- Sociology
Keywords Tag Cloud
glaxosmithkline gsk management merger dissertation pharmaceutical mergers change strategic om plc performance glaxo beecham financial wellcome corporate operations smithkline desired bring acquisition study effects proposal market system social stock strategy glaxowellcome quality value global vs organisational astrazeneca managing johnson impact model equilibrium technical newspaper construction disclosures environmental glaxosmithklein publicity using british pre pharmaceuticals acquisitions petroleum post smithline prediction annual pestel stocks swine intelligence safety clinical molecular shoeshine directions novartis pfizer companies audit innovation vaccines flu portfolio production uk healthcare responsibility faced issues reports control implementation valuation development role lean price critical process speeding share innovations intellectual systems soft critique knowledge methodology harbin project property negotiation approach backgrounds entrepreneurship announcement effect master return glaxosmithklines final culture benefit economic finance international risk c comparative benefits current position investigation overview options company
GET OUR GooGLE TOOLBAR BUTTON
BOOK MARK US
WHAT OTHERS HAVE SAID
Received thanx great paperJ.C.
